Overall, the non-canonical NF-κB pathway plays a crucial role in driving immune dysregulation and inflammation in SLE and more research is required to explore its capabilities as a possible therapeutic target in treatment this complex autoimmune disease. The gene discussed is NFKB1; the disease is systemic lupus erythematosus.